Boston Life Sciences, Inc. to Present at the 2007 Biotechnology Industry Organization's (BIO) Annual BIO International Conventio

HOPKINTON, Mass., May 1  /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Ken Rice, Executive Vice President and Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company overview in the Business Forum at the BIO International Convention Tuesday, May 8th at 11:45am EDT.  The conference is being held on May 6-9 at the Boston Convention & Exhibition Center in Boston, MA.

BIO is widely known for the BIO International Convention, a four-day annual biotechnology showcase that draws about 20,000 attendees. The convention serves to educate the public and policymakers about biotechnology, while fostering partnering meetings and other business development activities that keep the industry growing.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. The company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.

   Contact:  Sharon Correia -- 508-497-2360 ext 224
             Boston Life Sciences, Inc.
             

DATASOURCE: Boston Life Sciences, Inc.



CONTACT:  Sharon Correia of Boston Life Sciences, Inc., [phone],

ext. 224,  



Web site:  http://www.bostonlifesciences.com/

Copyright